State-owned PICC Property and Casualty signed China's first commercial insurance policy covering invasive brain-computer interface surgery on Wednesday 12 August 2026. Counterparty is the Second Affiliated Hospital of Zhejiang University School of Medicine. Zhejiang Provincial Government Office released a same-day industry-policy package. Hong Kong and Shenzhen BCI-tagged stocks rallied.
China has published its first national-level rulebook for how brain-computer interfaces should be built and how their data should be shared. Two recommended national standards, GB/T 47023-2026 and GB/T 47127-2026, took effect on 1 August 2026, setting a common technical vocabulary and a shared data format for Chinese BCI companies, hospitals, and researchers. A third standard covering visual-evoked-potential data follows on 1 October 2026. Jointly issued by SAMR and SAC. Published 28 January 2026.
BlueWind Medical received FDA 510(k) clearance on 5 August 2026 for Revi Extend, an updated version of its implantable posterior-tibial-nerve neuromodulation device with implant longevity extended from 10 to 15 years. Revi Extend is the second 510(k) in the Revi family; the base Revi System was authorised in August 2023 via FDA De Novo classification grant. OASIS three-year data supported the update. Revi is a peripheral-nerve stimulator, not a brain-computer interface, and is covered under InsideBCI's bioelectronic-medicine adjacency scope.
DARPA's Defense Sciences Office has posted Special Notice DARPA-SN-26-111 for its forthcoming SHINE (Selective Harnessing of Intrinsic Neuroplasticity Engineering) Disruption Opportunity, with a prerecorded Information Session webcast on 25 August 2026 and the DO release anticipated the same month. Program manager is Robin Bonomi. SHINE aims to non-invasively induce adaptive neuroplasticity in targeted dysfunctional neural circuits for injury recovery, spanning five modality domains. Awards will be Other Transactions for prototype projects. Registration closes 14 August 2026 and is unusually open to foreign nationals.
California Assemblymember Isaac Bryan's AB 1883, which regulates workplace surveillance including a specific prohibition on employer collection of neural data with a safety-use carve-out, has cleared the Assembly and moved most of the way through the Senate per CalMatters' 10 August 2026 tracking. A parallel Assembly Bill 1542 authored by Assemblymember Christopher Ward would prohibit the sale of neural data. Vermont S.71 (signed 16 June 2026) and H.814 (signed May 2026) are the most recent enacted comparators.
Duan Wanru of Xuanwu Hospital in Beijing said an experienced surgeon can position a Chinese endovascular brain-computer interface in as little as 10 minutes. StairMed unveiled a separate endovascular research program in December 2025 with the Chinese Academy of Sciences, currently in sheep testing. Nankai University completed China's first interventional human BCI in June 2025. Three Chinese endovascular BCI programs are now on the public record.
Researchers at KIST's Brain Science Institute have published a peer-reviewed BCI probe in Advanced Science that combines 416 electrodes and 832 photodiodes across 13 hair-thin silicon shanks, enabling simultaneous electrical and optical brain-signal readout on a single monolithic CMOS chip. KIST claims it as a world-first at this level of density and integration. Preclinical work in live mice; not yet in primate or human. Funded by Korea's K-Moonshot Project.
On 23 July 2026, Naomi Bashkansky resigned from OpenAI's alignment team after eighteen months to join Conduit, a San Francisco non-invasive brain-computer interface startup co-founded by Rio Popper and Clem von Stengel. Conduit claims to have collected approximately 10,000 hours of neuro-language data from thousands of paid participants over six months, funded through undisclosed capital. Bashkansky joins as Founding Researcher.
Shanghai Active Technology, founded February 2026, closed a RMB 330 million angel round announced on 3 August 2026. Gasgoo and 36Kr describe the raise as the largest single angel round in the Chinese BCI sector to date, though the lead investor was not disclosed. The company is building a full-link invasive BCI with three product lines including a 1024-channel motor system called Tianshu, which has obtained a type inspection report and is preparing to launch clinical trials.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.